Get the Stockscreener App
4.50
5.86%
-0.28
Sana Biotechnology Inc stock is traded at $4.50, with a volume of 4.44M.
It is down -5.86% in the last 24 hours and up +27.48% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
See More
Previous Close:
$4.78
Open:
$4.91
24h Volume:
4.44M
Relative Volume:
0.84
Market Cap:
$1.20B
Revenue:
-
Net Income/Loss:
$-252.18M
P/E Ratio:
-4.2453
EPS:
-1.06
Net Cash Flow:
$-185.29M
1W Performance:
-10.00%
1M Performance:
+27.48%
6M Performance:
+63.04%
1Y Performance:
+167.06%
1-Day Range:
$4.46
$5.05
1-Week Range:
$4.46
$5.36
52-Week Range:
$1.26
$7.30
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
4.50 | 1.27B | 0 | -252.18M | -185.29M | -1.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Wedbush | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Mar-18-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
How resilient is Sana Biotechnology Inc. stock in market downturns2025 Technical Patterns & Consistent Return Strategy Ideas - Улправда
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.5%Here's What Happened - MarketBeat
CFO Wyrick Acquires 2,527 Of Sana Biotechnology Inc [SANA] - TradingView — Track All Markets
Marex Group plc Takes $10.42 Million Position in Sana Biotechnology, Inc. $SANA - MarketBeat
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Breakout Move: How interest rate cuts could boost Sana Biotechnology Inc stockQuarterly Profit Review & AI Powered Buy/Sell Recommendations - moha.gov.vn
Sana Biotechnology Reports Reduced Losses and Strong Liquidity - MSN
Sana Biotechnology (NASDAQ:SANA) Trading Up 8.8%Still a Buy? - MarketBeat
Sana Biotechnology (SANA): Valuation Check After New In Vivo Gene Editing Data in Nature Biotechnology - Sahm
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Sana Biotechnology Stock: Soar or Sputter? - StocksToTrade
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.9%Time to Sell? - MarketBeat
Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform - The Manila Times
Sana Biotechnology Announces Publication in Nature - GlobeNewswire
Sana Biotechnology (NASDAQ: SANA) Nature Biotech data show in vivo HSC gene editing - Stock Titan
Buyout Rumor: How Sana Biotechnology Inc stock performs in weak economyNew Guidance & Daily Profit Maximizing Trade Tips - moha.gov.vn
Sana (SANA) Surges 14.5% Ahead of Business Announcements - MSN
Is Sana Biotechnology's (SANA) SC451 Pivot Quietly Redefining Its Long-Term Platform Strategy? - simplywall.st
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation - Quantisnow
Sana Biotechnology’s Surging Stock: Buy or Sell? - StocksToTrade
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Sana Biotechnology (NASDAQ:SANA) Trading Up 6.6%Should You Buy? - MarketBeat
Sana Biotechnology (SANA) Stock Analysis Report | Financials & Insights - Benzinga
Will Sana Biotechnology’s (SANA) Pipeline Focus Reveal Strategic Priorities in Diabetes and Autoimmune Innovation? - Yahoo Finance
Sana Biotechnology Beats Earnings Estimates, Prioritizes SC451 and CAR T - StocksToTrade
Sana Biotechnology Surges Amid Strong Q3 Earnings Performance - timothysykes.com
Sana Biotechnology (SANA): Assessing Valuation After Strong Year-to-Date Share Price Gains - Yahoo Finance
Sana Biotechnology (SANA): Evaluating Valuation After Recent Surge in Share Price - Sahm
10 Small Stocks with Mighty Gains - Insider Monkey
Sana Biotechnology (NASDAQ:SANA) Trading 12.8% HigherStill a Buy? - MarketBeat
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement - MSN
Sana Biotechnology to Present at December 2025 Investor Conferences - GlobeNewswire
Sana Biotechnology, Inc. to Webcast Presentations at December Investor Conferences - Quiver Quantitative
Sana Biotechnology (NASDAQ: SANA) to Present at 2025 Citi and Evercore Conferences - Stock Titan
Sana Biotechnology (NASDAQ:SANA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Citi Maintained a Buy Rating on Sana Biotechnology (SANA) - MSN
Why Sana Biotechnology Inc. stock could benefit from AI revolutionWatch List & Fast Gaining Stock Strategy Reports - newser.com
Can Sana Biotechnology Inc. stock deliver surprise earnings beat2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
How Sana Biotechnology Inc. stock benefits from global expansion2025 Biggest Moves & Free Reliable Trade Execution Plans - newser.com
Evaluating Sana Biotechnology Inc. with trendline analysisJuly 2025 Sentiment & Expert Curated Trade Ideas - newser.com
What valuation multiples suggest for Sana Biotechnology Inc. stock2025 Big Picture & Free AI Powered Buy and Sell Recommendations - newser.com
Using Ichimoku Cloud for Sana Biotechnology Inc. technicalsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Will Sana Biotechnology Inc. stock benefit from automationBull Run & Daily Risk Controlled Trade Plans - newser.com
The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care - Markets Financial Content
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):